Compare VFC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | IOVA |
|---|---|---|
| Founded | 1899 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.7B |
| IPO Year | 1994 | 2008 |
| Metric | VFC | IOVA |
|---|---|---|
| Price | $19.37 | $6.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 9 |
| Target Price | ★ $20.41 | $14.50 |
| AVG Volume (30 Days) | 10.0M | ★ 12.8M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 233.33 | 14.84 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $10,488,556,000.00 | N/A |
| Revenue This Year | N/A | $58.86 |
| Revenue Next Year | $3.03 | $41.86 |
| P/E Ratio | $31.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.46 | $2.08 |
| 52 Week High | $22.27 | $15.37 |
| Indicator | VFC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 28.53 |
| Support Level | $15.83 | $3.57 |
| Resistance Level | $19.71 | $9.36 |
| Average True Range (ATR) | 0.82 | 0.56 |
| MACD | -0.23 | -0.12 |
| Stochastic Oscillator | 2.74 | 1.30 |
VF designs, produces, and distributes apparel, footwear, and accessories with a focus on active and outdoor brands. Its portfolio of 10 labels includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and company-owned and partner-owned branded stores. Tracing its roots to 1899, VF has evolved into its present form through many brand acquisitions and divestitures.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.